| Literature DB >> 31176952 |
Na Luo1, Lin Tian2, Vince D Calhoun3, Jiayu Chen4, Dongdong Lin4, Victor M Vergara4, Shuquan Rao5, Jian Yang6, Chuanjun Zhuo7, Yong Xu8, Jessica A Turner9, Fuquan Zhang10, Jing Sui11.
Abstract
The progress of schizophrenia at various stages is an intriguing question, which has been explored to some degree using single-modality brain imaging data, e.g. gray matter (GM) or functional connectivity (FC). However it remains unclear how those changes from different modalities are correlated with each other and if the sensitivity to duration of illness and disease stages across modalities is different. In this work, we jointly analyzed FC, GM volume and single nucleotide polymorphisms (SNPs) data of 159 individuals including healthy controls (HC), drug-naïve first-episode schizophrenia (FESZ) and chronic schizophrenia patients (CSZ), aiming to evaluate the links among SNP, FC and GM patterns, and their sensitivity to duration of illness and disease stages in schizophrenia. Our results suggested: 1) both GM and FC highlighted impairments in hippocampal, temporal gyrus and cerebellum in schizophrenia, which were significantly correlated with genes like SATB2, GABBR2, PDE4B, CACNA1C etc. 2) GM and FC presented gradually decrease trend (HC > FESZ>CSZ), while SNP indicated a non-gradual variation trend with un-significant group difference observed between FESZ and CSZ; 3) Group difference between HC and FESZ of FC was more remarkable than GM, and FC presented a stronger negative correlation with duration of illness than GM (p = 0.0006). Collectively, these results highlight the benefit of leveraging multimodal data and provide additional clues regarding the impact of mental illness at various disease stages.Entities:
Keywords: Duration of illness; ICA; Multimodal fusion; SNP-FC-GM; Schizophrenia stages; Sensitivity
Mesh:
Year: 2019 PMID: 31176952 PMCID: PMC6558215 DOI: 10.1016/j.nicl.2019.101887
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Demographic characteristics of the subjects in the present study.
| Demographics | HC | FESZ | CSZ | ||
|---|---|---|---|---|---|
| Number | 87 | 20 | 52 | ||
| Gender | M/F | 47/40 | 10/10 | 30/22 | 0.83 |
| Age (y) | Mean ± SD | 39.91 ± 14.84 | 33.60 ± 10.80 | 46.12 ± 11.38 | 0.0011 |
| Education | Mean ± SD | 12.67 ± 4.28 | 10.65 ± 4.65 | 10.75 ± 2.69 | 0.0091 |
| Duration of Illness (y) | Mean ± SD | NA | 0.96 ± 0.85 | 20.63 ± 9.84 | |
| Chlorpromazine Equivalent | Mean ± SD | NA | Drug-naïve | 17.26 ± 9.44 | |
| PANSS positive | Mean ± SD | NA | 27.8 ± 4.64 | 19.62 ± 3.82 | 9.20E-08 |
| PANSS negative | Mean ± SD | NA | 19.65 ± 4.78 | 24.40 ± 3.52 | 3.87E-04 |
| PANSS general | Mean ± SD | NA | 46.45 ± 7.49 | 41.77 ± 5.11 | 0.016 |
Note: Chlorpromazine equivalent = Chlorpromazine total (standardized current dose of antipsychotic medication). P values represent the results of chi-square test for gender, analysis of variance (ANOVA) test for age and education, two sample t-test for PANSS scores. HC: healthy control subjects; FESZ: first-episode schizophrenia; CSZ: chronic schizophrenia; F: female; M: male; NA: not applicable.
Fig. 1Analysis pipeline of the study. We firstly applied three-way para-ICA on the healthy controls (HC), first-episode schizophrenia (FESZ) and chronic schizophrenia (CSZ) subjects with three modalities [Single nucleotide polymorphism (SNP), functional connectivity (FC) and gray matter (GM)] to identify a linked SNP-FC-GM pattern. Afterwards, ANOVA analysis and two sample t-test were used to measure the group difference across groups for the linked SNP-FC-GM pattern. We further plotted the relationship between the identified imaging modalities and duration of illness (DOI), and used the slopes to compare sensitivity for FC and GM.
Fig. 2The pairwise correlation plots of the identified SNP-FC-GM component. (A) The correlation among FC, GM and SNP modalities before regressing out any variables. (B) The correlation among FC, GM and SNP modalities after regressing out age, gender, education and diagnosis. Note: The blue dots represent the healthy controls(HC). The red dots represent the chronic schizophrenia patients (CSZ). The green dots represent the first-episode schizophrenia patients(FESZ).
Fig. 3Different sensitivity to disease stages and DOI. (A) ANOVA and two-sample t-tests within each modality. Note: The p-values display results of ANOVA analysis. The red violin plot represents healthy controls (HC). The green violin plot represents first-episode schizophrenia patients (FESZ). The blue violin plot represents the chronic schizophrenia patients (CSZ). *represent 0.00001 < p < 0.05, ** represents 1e-5 < p < 1e-10, **represents p < 1e-10. (B)Different sensitivity comparison between the GM and FC modality to DOI. Note: the gray and black dots represent correlation between GM, FC loadings and DOI respectively. The gray and black regression lines represent the slope of the correlation. The two-tailed p-value of the z values between two slopes is significant (p = 0.00063).
Fig. 4The abnormal brain regions and functional connectivity revealed by three-way para-ICA. (A) Brain regions showing gray matter abnormalities in the SNP-FC-GM pattern. The red regions represent gray matter decrease in SZ while the blue regions represent gray matter increase in SZ. (B) Imparied FC identified from the SNP-FC-GM pattern. The red connecting lines represent FC decrease in SZ, while the blue connecting lines represent FC increase in SZ.
Fig. 5Mahattan plot and GO analysis of the joint SNP component. (A) Manhattan plot of the identified SNP component. (B) GO analysis results of the high-ranking SNP with |Z-scores| > 2; P-values are all FDR corrected.